Menu

Institute
  • Neurology Unit
  • Back

    Dr Laura Hughes

    University Position
    Research Associate

    Interests

    My current research interests are on the role of the prefrontal cortex for voluntary and goal directed actions, and prefrontal interactions with other brain systems. I use both MEG and fMRI, along with behavioural and neuropsychological data, to investigate healthy adults and patients with neurodegenerative diseases (such as Parkinson's disease and frontotemporal dementia) and patients with brain lesions (for example due to tumors or stroke). I collaborate with James Rowe and our aim is to understand the cortical networks of the intact brain and to assess changes related to disease.

    Key Publications

    Publications

    Neurochemistry-enriched dynamic causal models of magnetoencephalography, using magnetic resonance spectroscopy.

    DOI: http://doi.org/10.1016/j.neuroimage.2023.120193
    Journal: Neuroimage
    E-pub date: 1 Aug 2023
    Authors: A Jafarian, LE Hughes, NE Adams, JH Lanskey, M Naessens, MA Rouse, AG Murley, KJ Friston, JB Rowe

    Neurophysiological consequences of synapse loss in progressive supranuclear palsy.

    DOI: http://doi.org/10.1093/brain/awac471
    Journal: Brain
    E-pub date: 1 Jun 2023
    Authors: NE Adams, A Jafarian, A Perry, MA Rouse, AD Shaw, AG Murley, TE Cope, WR Bevan-Jones, L Passamonti, D Street, N Holland, D Nesbitt, LE Hughes, KJ Friston, JB Rowe

    Neurophysiological consequences of synapse loss in progressive supranuclear palsy

    DOI: http://doi.org/10.1101/2022.06.22.22276697
    Journal:
    E-pub date: 1 Aug 2022
    Authors: N Adams, A Jafarian, A Perry, M Rouse, A Shaw, A Murley, T Cope, R Bevan-Jones, L Passamonti, D Street, N Holland, D Nesbitt, L Hughes, K Friston, J Rowe

    Causal Evidence for the Multiple Demand Network in Change Detection: Auditory Mismatch Magnetoencephalography across Focal Neurodegenerative Diseases.

    DOI: http://doi.org/10.1523/JNEUROSCI.1622-21.2022
    Journal: J Neurosci
    E-pub date: 13 Apr 2022
    Authors: TE Cope, LE Hughes, HN Phillips, NE Adams, A Jafarian, D Nesbitt, M Assem, A Woolgar, J Duncan, JB Rowe

    Towards accurate and unbiased imaging-based differentiation of Parkinson’s disease, progressive supranuclear palsy and corticobasal syndrome.

    DOI: http://doi.org/10.1093/braincomms/fcaa051
    Journal: Brain Commun
    E-pub date: 1 Aug 2020
    Authors: MM Correia, T Rittman, CL Barnes, IT Coyle-Gilchrist, B Ghosh, LE Hughes, JB Rowe

    GABA-ergic Dynamics in Human Frontotemporal Networks Confirmed by Pharmaco-Magnetoencephalography.

    DOI: http://doi.org/10.1523/JNEUROSCI.1689-19.2019
    Journal: J Neurosci
    E-pub date: 19 Feb 2020
    Authors: NE Adams, LE Hughes, HN Phillips, AD Shaw, AG Murley, D Nesbitt, TE Cope, WR Bevan-Jones, L Passamonti, JB Rowe

    Atomoxetine and citalopram alter brain network organization in Parkinson’s disease.

    DOI: http://doi.org/10.1093/braincomms/fcz013
    Journal: Brain Commun
    E-pub date: 1 Aug 2019
    Authors: RJ Borchert, T Rittman, CL Rae, L Passamonti, SP Jones, D Vatansever, P Vázquez Rodríguez, Z Ye, C Nombela, LE Hughes, TW Robbins, JB Rowe

    Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia.

    DOI: http://doi.org/10.1093/brain/awy176
    Journal: Brain
    E-pub date: 1 Aug 2018
    Authors: LE Hughes, T Rittman, TW Robbins, JB Rowe

    Neurophysiological signatures of Alzheimer’s disease and frontotemporal lobar degeneration: pathology versus phenotype.

    DOI: http://doi.org/10.1093/brain/awy180
    Journal: Brain
    E-pub date: 1 Aug 2018
    Authors: S Sami, N Williams, LE Hughes, TE Cope, T Rittman, ITS Coyle-Gilchrist, RN Henson, JB Rowe

    Monitoring the past and choosing the future: the prefrontal cortical influences on voluntary action.

    DOI: http://doi.org/10.1038/s41598-018-25127-y
    Journal: Sci Rep
    E-pub date: 8 May 2018
    Authors: HN Phillips, TE Cope, LE Hughes, J Zhang, JB Rowe

    Atomoxetine restores the response inhibition network in Parkinson’s disease.

    DOI: http://doi.org/10.1093/brain/aww138
    Journal: Brain
    E-pub date: 31 Aug 2016
    Authors: CL Rae, C Nombela, PV Rodríguez, Z Ye, LE Hughes, PS Jones, T Ham, T Rittman, I Coyle-Gilchrist, R Regenthal, BJ Sahakian, RA Barker, TW Robbins, JB Rowe

    Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson’s Disease.

    DOI: http://doi.org/10.1038/npp.2016.18
    Journal: Neuropsychopharmacology
    E-pub date: 1 Jul 2016
    Authors: RJ Borchert, T Rittman, L Passamonti, Z Ye, S Sami, SP Jones, C Nombela, P Vázquez Rodríguez, D Vatansever, CL Rae, LE Hughes, TW Robbins, JB Rowe

    Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson’s Disease.

    DOI: http://doi.org/10.1038/npp.2016.46
    Journal: Neuropsychopharmacology
    E-pub date: 1 Jul 2016
    Authors: RJ Borchert, T Rittman, L Passamonti, Z Ye, S Sami, SP Jones, C Nombela, PV Rodríguez, D Vatansever, CL Rae, LE Hughes, TW Robbins, JB Rowe

    Improving response inhibition systems in frontotemporal dementia with citalopram.

    DOI: http://doi.org/10.1093/brain/awv133
    Journal: Brain
    E-pub date: 1 Jul 2015
    Authors: LE Hughes, T Rittman, R Regenthal, TW Robbins, JB Rowe

    The val158met COMT polymorphism’s effect on atrophy in healthy aging and Parkinson’s disease.

    DOI: http://doi.org/10.1016/j.neurobiolaging.2008.07.009
    Journal: Neurobiol Aging
    E-pub date: 1 Jun 2010
    Authors: JB Rowe, L Hughes, CH Williams-Gray, S Bishop, S Fallon, RA Barker, AM Owen

    Parkinson’s disease and dopaminergic therapy–differential effects on movement, reward and cognition.

    DOI: http://doi.org/10.1093/brain/awn112
    Journal: Brain
    E-pub date: 31 Aug 2008
    Authors: JB Rowe, L Hughes, BCP Ghosh, D Eckstein, CH Williams-Gray, S Fallon, RA Barker, AM Owen